Q3 2018 13F Holders as of 30 Sep 2018
-
Type / Class
-
Equity / ADR
-
Shares outstanding
-
55.6M
-
Number of holders
-
94
-
Total 13F shares, excl. options
-
40.2M
-
Shares change
-
+616K
-
Total reported value, excl. options
-
$2.85B
-
Value change
-
+$44.5M
-
Put/Call ratio
-
1.41
-
Number of buys
-
49
-
Number of sells
-
-43
-
Price
-
$70.86
Significant Holders of Ascendis Pharma A/S - ADR (ASND) as of Q3 2018
112 filings reported holding ASND - Ascendis Pharma A/S - ADR as of Q3 2018.
Ascendis Pharma A/S - ADR (ASND) has 94 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 40.2M shares
of 55.6M outstanding shares and own 72.31% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, LLC (4.24M shares), ORBIMED ADVISORS LLC (4.16M shares), FMR LLC (4.15M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.38M shares), BAKER BROS. ADVISORS LP (2.84M shares), Sofinnova Ventures Inc (2.48M shares), Vivo Capital, LLC (2.17M shares), venBio Select Advisor LLC (1.96M shares), EVENTIDE ASSET MANAGEMENT, LLC (1.54M shares), and FARALLON CAPITAL MANAGEMENT LLC (1.46M shares).
This table shows the top 94 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.